Research and Markets: CAR-T Therapies in Oncology Drug Pipeline Report 2015

Research and Markets (http://www.researchandmarkets.com/research/bmm4d9/cart_therapies) has announced the addition of the "CAR-T Therapies in Oncology Drug Pipeline Update 2015" report to their offering.

Chimeric antigen receptors (CARs) are a game changer within cancer therapies and there will be a place in history and huge recognition for any company which is able to launch the first successful CAR-T therapy drug. In this regard, we have already witnessed the stellar results by Novartis and Penn University on CTL019 that left 92% of patients cancer-free in a leukemia study and performed well against lymphomas in clinical trial results presented at the annual American Society of Hematology (ASH) meeting, stirring hopes that the treatment can change the standard of care for blood cancers.

More-over, the CAR-T Therapies in Oncology Drug Pipeline Update is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in cancer immunology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your CAR-T intelligence.

There are today 15 companies plus partners developing 39 CAR-T drugs in 76 developmental projects in cancer. CAR-T Therapies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 26 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 25 out of the 25 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 11 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs

• Phase II - 5
• Phase I - 9
• Preclinical - 10
• Discovery - 16
  

Delivery Format: Desktop App plus Online Access to Updates (One Year)

For more information visit http://www.researchandmarkets.com/research/bmm4d9/cart_therapies